Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy

Fujimoto Daichi; Yoshioka Hiroshige; Kataoka Yuki; Morimoto Takeshi; Hata Tae; Kim Young Hak; Tomii Keisuke; Ishida Tadashi; Hirabayashi Masataka; Hara Satoshi; Ishitoko Manabu; Fukuda Yasushi; Hwang Moon Hee; Sakai Naoki; Fukui Motonari; Nakaji Hitoshi; Morita Mitsunori; Mio Tadashi; Yasuda Takehiro; Sugita Takakazu; Hirai Toyohiro

首页> 外文期刊>Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer >Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy

【24h】

Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy

机译：先前治疗的非小细胞肺癌患者的假冒突出，接受Nivolumab单药治疗

获取原文

获取原文并翻译 | 示例

掌桥外文数据库（机构版） >>

开具论文收录证明 >>

文献代查 >>

页面导航

摘要
著录项
相似文献
相关主题

摘要

Introduction: Nivolumab is effective in the treatment of previously treated patients with advanced NSCLC. However, its radiological evaluation is challenging because of atypical patterns of response such as pseudoprogression. We examined the characteristics and outcomes of previously treated patients with NSCLC who were treated with nivolumab and experienced development of pseudoprogression.

机译：简介：Nivolumab在治疗先前治疗先进的NSCLC患者方面是有效的。然而，由于非典型反应模式，其放射性评估是具有挑战性的，例如假冒竞争。我们研究了先前治疗的NSCLC患者的特征和结果，他用Nivolumab治疗并经历了假冒竞争的发展。

著录项

来源
《Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer》 |2019年第3期|共7页
作者
Fujimoto Daichi; Yoshioka Hiroshige; Kataoka Yuki; Morimoto Takeshi; Hata Tae; Kim Young Hak; Tomii Keisuke; Ishida Tadashi; Hirabayashi Masataka; Hara Satoshi; Ishitoko Manabu; Fukuda Yasushi; Hwang Moon Hee; Sakai Naoki; Fukui Motonari; Nakaji Hitoshi; Morita Mitsunori; Mio Tadashi; Yasuda Takehiro; Sugita Takakazu; Hirai Toyohiro;
展开▼
作者单位

Kobe City Med Ctr Gen Hosp Dept Resp Med Kobe Hyogo Japan;

Kurashiki Cent Hosp Dept Resp Med Kurashiki Okayama Japan;

Hyogo Prefectural Amagasaki Gen Med Ctr Dept Resp Med Amagasaki Hyogo Japan;

Kobe City Med Ctr Gen Hosp Clin Res Ctr Kobe Hyogo Japan;

Kurashiki Cent Hosp Dept Resp Med Kurashiki Okayama Japan;

Kyoto Univ Hosp Dept Resp Med Kyoto Japan;

Kobe City Med Ctr Gen Hosp Dept Resp Med Kobe Hyogo Japan;

Kurashiki Cent Hosp Dept Resp Med Kurashiki Okayama Japan;

Hyogo Prefectural Amagasaki Gen Med Ctr Dept Resp Med Amagasaki Hyogo Japan;

Itami City Hosp Dept Resp Med Itami Hyogo Japan;

Shiga Gen Hosp Dept Resp Med Moriyama Japan;

Himeji Med Ctr Dept Resp Med Himeji Hyogo Japan;

Osaka Red Cross Hosp Dept Resp Med Osaka Japan;

Otsu Red Cross Hosp Dept Resp Med Otsu Shiga Japan;

Tazuke Kofukai Med Res Inst Resp Dis Ctr Kitano Hosp Osaka Japan;

Toyooka Publ Hosp Dept Resp Med Toyooka Japan;

Kobe City Med Ctr West Hosp Dept Resp Med Kobe Hyogo Japan;

Natl Hosp Org Kyoto Med Ctr Dept Resp Med Kyoto Japan;

Tenri Hosp Dept Resp Med Nara Japan;

Japanese Red Cross Wakayama Med Ctr Dept Resp Med Wakayama Japan;

Kyoto Univ Hosp Dept Resp Med Kyoto Japan;

展开▼
收录信息
原文格式 PDF
正文语种 eng
中图分类肿瘤学;
关键词
PD-1; PD-L1; Pseudoprogression; Immune checkpoint inhibitor; Nivolumab;

机译：PD-1;PD-L1;假冒竞争;免疫检查点抑制剂;Nivolumab;

相似文献

外文文献
中文文献
专利

1. Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy [J] . Fujimoto Daichi, Yoshioka Hiroshige, Kataoka Yuki, Journal of thoracic oncology: official publication of the International Association for the Study of Lung Cancer . 2019,第3期

机译：先前治疗的非小细胞肺癌患者的假冒突出，接受Nivolumab单药治疗
2. Nivolumab (Anti-PD-1; BMS-936558, ONO-4538) Maintenance as Monotherapy or in Combination With Bevacizumab (BEV) for Non-Small Cell Lung Cancer (NSCLC) Previously Treated With Chemotherapy [J] . Rizvi N. A., Antonia S. J., Shepherd F. A., International Journal of Radiation Oncology, Biology, Physics . 2014,第5Suppla期

机译：Nivolumab（Anti-PD-1; BMS-936558，ONO-4538）单一治疗或与贝伐单抗（BEV）联合用于先前用化学疗法治疗的非小细胞肺癌（NSCLC）的维持
3. Diffuse pseudoprogression in a patient with metastatic non-small-cell lung cancer treated with Nivolumab [J] . Curioni-Fontecedro A., Ickenberg C., Franzen D., Annals of oncology: official journal of the European Society for Medical Oncology . 2017,第8期

机译：弥漫于用Nivolumab处理的转移性非小细胞肺癌的患者中弥漫症
4. IMPROVING PREDICTION OF SURVIVAL USING CT-BASED TUMOR CHARACTERISTICS IN PATIENTS TREATED FOR METASTATIC NON-SMALL CELL LUNG CANCER [C] . WALKER H. LAND JR., ALAN LITWIN, DAN MARGOLIS, Artificial Neural Networks in Engineering Conference . 2010

机译：基于CT基肿瘤特征改善对转移性非小细胞肺癌的患者的肿瘤特征预测
5. Assessing the effectiveness of palliative chemotherapy for non-small cell lung cancer: A phase IV study of patients treated at Ontario's cancer centres [D] . Harrison, Lyndsay Dawn. 2012

机译：评估姑息化疗对非小细胞肺癌的有效性：在安大略省癌症中心接受治疗的患者的IV期研究
6. Peritumoural ground-glass opacity associated with tumour pseudoprogression in a patient with non-small cell lung cancer treated with nivolumab [O] . Ryoji Kato, Hidetoshi Hayashi, Junko Tanizaki, 2017

机译：非诺贝单抗治疗的非小细胞肺癌患者的周围玻璃体混浊与肿瘤假进展相关
7. Pseudoprogression in Previously Treated Patients with Non–Small Cell Lung Cancer Who Received Nivolumab Monotherapy [O] . Daichi Fujimoto, Hiroshige Yoshioka, Yuki Kataoka, 2019

机译：先前治疗的非小细胞肺癌患者的假冒突出，接受Nivolumab单药治疗

Pseudoprogression in Previously Treated Patients with Non-Small Cell Lung Cancer Who Received Nivolumab Monotherapy

摘要

著录项

相似文献

相关主题

期刊订阅